- ITM deal
- $1.65B upfront
Telix Pharmaceuticals is a Melbourne radiopharmaceutical company developing and selling targeted imaging and therapy agents. In September 2026 it agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in milestones, adding a German isotope production and distribution network. ITM shareholders will own about 23.7 per cent of the combined company.